Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...
Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed ...
If you or a loved one took Zantac (ranitidine) and later developed health complications, particularly cancer, you may be entitled to legal compensation through a Zantac lawsuit. Due to increasing ...
British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.
A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...
Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.
UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.
GSK declared a third-quarter dividend of 15.00 pence per share, unchanged from the second quarter, but up 7.1% from 14.00p per share last year. It continues to expect a total dividend of 60.00p per ...